BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases

View More View Less
  • 1 Departments of Neurological Surgery and
  • 2 Radiation Oncology, University of Virginia, Charlottesville, Virginia;
  • 3 Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital;
  • 4 School of Medicine, National Yang-Ming University, Taipei; and
  • 5 Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Recent advancements in molecular biology have identified the BRAF mutation as a common mutation in melanoma. The wide use of BRAF kinase inhibitor (BRAFi) in patients with metastatic melanoma has been established. The objective of this study was to examine the impact of BRAF mutation status and use of BRAFi in conjunction with stereotactic radiosurgery (SRS).

METHODS

This was a single-center retrospective study. Patient's charts and electronic records were reviewed for date of diagnosis of primary malignancy, BRAF mutation status, chemotherapies used, date of the diagnosis of CNS metastases, date of SRS, survival, local tumor control after SRS, and adverse events. Patients were divided into 3 groups: Group A, those with mutant BRAF without BRAFi treatment (13 patients); Group B, those with mutant BRAF with BRAFi treatment (17 patients); and Group C, those with wild-type BRAF (35 patients). Within a cohort of 65 patients with the known BRAF mutation status and treated with SRS between 2010 and 2014, 436 individual brain metastases (BMs) were identified. Kaplan-Meier methodology was then used to compare survival based on each binary parameter.

RESULTS

Median survival times after the diagnosis of melanoma BM and after SRS were favorable in patients with a BRAF mutation and treated with SRS in conjunction with BRAFi (Group B) compared with the patients with wild-type BRAF (Group C, 23 vs 8 months and 13 vs 5 months, respectively; p < 0.01, log-rank test). SRS provided a local tumor control rate of 89.4% in the entire cohort of patients. Furthermore, the local control rate was improved in the patients treated with SRS in conjunction with BRAFi (Group B) compared with patients with wild-type (Group C) or with BRAF mutation but no BRAFi (Group A) as an adjunct treatment for BMs.

CONCLUSIONS

BRAF mutation status appears to play an important role as a potent prognostic factor in patients harboring melanoma BM. BRAFi in conjunction with SRS may benefit this group of patients in terms of BM survival and SRS with an acceptable safety profile.

ABBREVIATIONSARE = adverse radiation effect; BM = brain metastasis; BRAFi = BRAF kinase inhibitor; DS-GPA = disease-specific graded prognostic assessment; GKRS = Gamma Knife radiosurgery; KPS = Karnofsky Performance Scale; MEK = mitogen-activated protein kinase; OS = overall survival; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

INCLUDE WHEN CITING Published online May 20, 2016; DOI: 10.3171/2016.2.JNS1633.

Correspondence Jason P. Sheehan, Department of Neurological Surgery, University of Virginia, Box 800212, Charlottesville, VA 22908. email: jsheehan@virginia.edu.
  • 1

    Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, : Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:16951701, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, : Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283e287, 2013

    • Search Google Scholar
    • Export Citation
  • 3

    Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, : Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:32053211, 2013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Azer MW, Menzies AM, Haydu LE, Kefford RF, Long GV: Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120:530536, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Balakan O, Süner A, Yiğiter R, Balakan T, Sirikçi A, Sevinç A: Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med 51:28192823, 2012

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, : BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer 50:26682676, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Burgeiro A, Mollinedo F, Oliveira PJ: Ipilimumab and vemurafenib: two different routes for targeting melanoma. Curr Cancer Drug Targets 13:879894, 2013

  • 8

    Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, : Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123:223233, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, : Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15:94100, 2013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, : BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:25222529, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, : Mutations of the BRAF gene in human cancer. Nature 417:949954, 2002

  • 12

    Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, : Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611621, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, : Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:18931901, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, : Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:12931300, 2004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Fuentes S, Delsanti C, Metellus P, Peragut JC, Grisoli F, Regis J: Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery 58:3742, 2006

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, : Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745751, 1997

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, : On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 25:20862091, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, Bonerandi JJ, : Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 65:809816, 2006

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Jang S, Atkins MB: Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 14:e60e69, 2013

  • 20

    Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL: Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227233, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, : Ipilimumab in melanoma patients with brain metastasis: a retrospective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 94:4549, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795803, 1999

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Liebner DA, Walston SA, Cavaliere R, Powers CJ, Sauvageau E, Lehman NL, : Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res 24:172176, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, : Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 114:769779, 2011

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, : Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:10871095, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, : Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 123:395401, 2015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, : Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18:32423249, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L: Gamma surgery for melanoma metastases in the brain. J Neurosurg 96:544551, 2002

  • 29

    Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, : Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411416, 2013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Partl R, Fastner G, Kaiser J, Kronhuber E, Cetin-Strohmer K, Steffal C, : KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy. Support Care Cancer 24:523528, 2016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31

    Radbill AE, Fiveash JF, Falkenberg ET, Guthrie BL, Young PE, Meleth S, : Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101:825833, 2004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Sampson JH, Carter JH Jr, Friedman AH, Seigler HF: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:1120, 1998

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33

    Selek U, Chang EL, Hassenbusch SJ III, Shiu AS, Lang FF, Allen P, : Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59:10971106, 2004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Sheehan JP, Yen CP, Nguyen J, Rainey JA, Dassoulas K, Schlesinger DJ: Timing and risk factors for new brain metastasis formation in patients initially treated only with Gamma Knife surgery. Clinical article. J Neurosurg 114:763768, 2011

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Snell JW, Sheehan J, Stroila M, Steiner L: Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. Technical note. J Neurosurg 104:157162, 2006

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510514, 2008

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, : Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82:21112117, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, : Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419425, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG, : Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 127:607615, 2016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40

    Wu S, Kuo H, Li WQ, Canales AL, Han J, Qureshi AA: Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. Cancer Causes Control 25:13791386, 2014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41

    Xu Z, Elsharkawy M, Schlesinger D, Sheehan J: Gamma knife radiosurgery for resectable brain metastasis. World Neurosurg 80:351358, 2013

  • 42

    Xu Z, Schlesinger D, Toulmin S, Rich T, Sheehan J: Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases. Int J Radiat Oncol Biol Phys 84:612618, 2012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43

    Yu C, Chen JC, Apuzzo ML, O'Day S, Giannotta SL, Weber JS, : Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52:12771287, 2002

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 384 24 0
Full Text Views 536 189 10
PDF Downloads 311 88 12
EPUB Downloads 0 0 0